Sign in
LABP Stock Price, Chart, Stats & News
Landos Biopharma, Inc.
Save
71.68M
Market cap
–
Current P/E
–
Forward P/E
LABP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -57.66% |
ROE | -61.86% |
D/E | – |
Interest coverage ratio | – |
LABP valuation
P/E | – |
P/S | – |
P/B | 4.53x |
P/CF | -7.03x |
P/FCF | -3.50x |
P/OCF | -7.03x |
PEG | -0.07x |
EV multiple | -4.82x |
About
Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis.
Similar securities
Based on sector and market capitalization
Report issue